PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34161207-9	2022	Nitrofurantoin, gentamycin, and imipenem were the most effective antibiotics for ESBL-producing E. coli isolates.	Nitrofurantoin	0-14	EsbL	Escherichia coli	81-85	
32120467-8	2019	ABST of ESBL producers revealed high resistance rates for quinolones (41%) and   >80%   sensitivity   for   nitrofurantoin, fosfomycin, mecillinam, aminoglycosides and carbapenems.	Nitrofurantoin	108-122	EsbL	Escherichia coli	8-12	
32120467-12	2019	>80% ESBL   organisms   show   high sensitivity   for aminoglycosides, carbapenems, nitrofurantoin, mecillinam and fosfomycin.	Nitrofurantoin	84-98	EsbL	Escherichia coli	5-9	
26414659-13	2016	CONCLUSIONS: Overall, the in vitro susceptibility to nitrofurantoin, fosfomycin, mecillinam and temocillin was high, indicating that these drugs are good options for treating uncomplicated urinary tract infections caused by ESBL-producing E. coli.	Nitrofurantoin	53-67	EsbL	Escherichia coli	224-228	
28992981-10	2018	Fosfomycin and nitrofurantoin were very active on E. coli ESBL.	Nitrofurantoin	15-29	EsbL	Escherichia coli	58-62	
27092771-7	2016	More than 95% of non extended-spectrum beta-lactamase (ESBL)-producing E. coli were susceptible to nitrofurantoin, fosfomycin, cefotaxime and aminoglycosides.	Nitrofurantoin	99-113	EsbL	Escherichia coli	55-59	
29563719-7	2018	Colistin and fosfomycin remains the most sensitive antibiotic while nitrofurantoin still preserves the good sensitivity against ESBL and found to be an only oral sensitive antibiotic.	Nitrofurantoin	68-82	EsbL	Escherichia coli	128-132	
28377310-1	2017	OBJECTIVE: To verify the role of proton pump inhibitors (PPI) and nitrofurantoin, which have appeared as novel risk factors for carriage of extended-spectrum beta-lactamase (ESBL) -producing Escherichia coli, as risk factors for ESBL E. coli urinary tract infection (UTI).	Nitrofurantoin	66-80	EsbL	Escherichia coli	140-172	
26167826-16	2015	According to the results of our study, the most effective drugs for ESBL-producing isolates were piperacillin-tazobactam among inhibitor combinations, amikacin among aminoglycosides and nitrofurantoin among orally-used drugs.	Nitrofurantoin	186-200	EsbL	Escherichia coli	68-72	
24666610-6	2014	For ESBL-producing E. coli isolates, resistance to both ciprofloxacin and trimethoprim-sulfamethoxazole was 95% and 65%, respectively but 94% of isolates were susceptible to nitrofurantoin.	Nitrofurantoin	174-188	EsbL	Escherichia coli	4-8	
26120573-15	2014	The ESBL producers were highly susceptible to imipenem (95%), nitrofurantoin (66%) but less susceptible to ampicillin (4%) and ticarcillin (7%).	Nitrofurantoin	62-76	EsbL	Escherichia coli	4-8	
25179392-3	2014	We conducted a retrospective study of 36 outpatients aged >18 years with dysuria or problems with frequency or urgency in passing urine; pyuria and a positive urine culture (10(5) cfu/ml) for ESBL producing Ec or Kp which is also resistant to nitrofurantoin, fosfomycin, quinolones and trimethoprim/sulfamethoxazole, between January 2013 and February 2014.	Nitrofurantoin	246-260	EsbL	Escherichia coli	195-199	
22508296-4	2012	Nosocomial and nonnosocomial ESBL-producing E. coli isolates had similar susceptibility profiles, while nonnosocomial ESBL-producing K. pneumoniae was associated with decreased ciprofloxacin (P = 0.03) and nitrofurantoin (P < 0.001) susceptibilities.	Nitrofurantoin	206-220	EsbL	Escherichia coli	118-122	
24502096-13	2013	CONCLUSION: This study has demonstrated the presence of ESBL producing E. coli urinary isolates in outpatients, and their extensive susceptibility to imipenem and nitrofurantoin.	Nitrofurantoin	163-177	EsbL	Escherichia coli	56-60	
22882781-7	2012	The proportion of ESBL-producing bacteria that were resistant to antibiotics was 83.1% for trimethoprim/sulfamethoxazole, 18.2% for nitrofurantoin, 47.3% for quinolones, and 39.9% for aminoglycosides.	Nitrofurantoin	132-146	EsbL	Escherichia coli	18-22	
22882781-8	2012	For non-ESBL-producing bacteria, the resistance rate was 62.2% for trimethoprim/sulfamethoxazole, 4.6% for nitrofurantoin, 9.7% for quinolones, and 9.7% for aminoglycosides.	Nitrofurantoin	107-121	EsbL	Escherichia coli	8-12	
20387724-6	2010	ESBL-producing K. pneumoniae showed high resistance rates to aminoglycosides, cotrimoxazole, nitrofurantoin and quinolones while ESBL-producing E. coli isolates, with exception of high aminoglycoside resistance, showed low resistance rates to other antibiotics.	Nitrofurantoin	93-107	EsbL	Escherichia coli	0-4	
18154548-6	2008	However, among 115 clinical isolates of E. coli ESBL producers, only 71.3% were sensitive to nitrofurantoin.	Nitrofurantoin	93-107	EsbL	Escherichia coli	48-52	
18423165-10	2008	The 68.6% of ESBL-producing E.coli were resistant to cotrimoxazole, 72.2% to ciprofloxacin vs 10.6% to nitrofurantoin and 1.9% to phosphomycin.	Nitrofurantoin	103-117	EsbL	Escherichia coli	13-17	
17642726-4	2004	The susceptibility of ESBL producers to imipenem, nitrofurantoin and amikacin was found to be 100%, 89% and 86% respectively.	Nitrofurantoin	50-64	EsbL	Escherichia coli	22-26